716 related articles for article (PubMed ID: 28277807)
1. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).
Han MA; Saouaf R; Ayoub W; Todo T; Mena E; Noureddin M
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):379-390. PubMed ID: 28277807
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
3. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
5. Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
Ajmera V; Loomba R
Semin Liver Dis; 2018 Feb; 38(1):14-20. PubMed ID: 29471562
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease.
Gu Q; Cen L; Lai J; Zhang Z; Pan J; Zhao F; Yu C; Li Y; Chen C; Chen W; Shen Z
Eur J Clin Invest; 2021 Feb; 51(2):e13446. PubMed ID: 33128454
[TBL] [Abstract][Full Text] [Related]
7. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants.
Hsu C; Caussy C; Imajo K; Chen J; Singh S; Kaulback K; Le MD; Hooker J; Tu X; Bettencourt R; Yin M; Sirlin CB; Ehman RL; Nakajima A; Loomba R
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):630-637.e8. PubMed ID: 29908362
[TBL] [Abstract][Full Text] [Related]
9. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
10. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
Singh S; Muir AJ; Dieterich DT; Falck-Ytter YT
Gastroenterology; 2017 May; 152(6):1544-1577. PubMed ID: 28442120
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
12. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity.
Ooi GJ; Earnest A; Kemp WW; Burton PR; Laurie C; Majeed A; Johnson N; McLean C; Roberts SK; Brown WA
Int J Obes (Lond); 2018 Nov; 42(11):1900-1911. PubMed ID: 29463916
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.
Troelstra MA; Witjes JJ; van Dijk AM; Mak AL; Gurney-Champion O; Runge JH; Zwirs D; Stols-Gonçalves D; Zwinderman AH; Ten Wolde M; Monajemi H; Ramsoekh S; Sinkus R; van Delden OM; Beuers UH; Verheij J; Nieuwdorp M; Nederveen AJ; Holleboom AG
J Magn Reson Imaging; 2021 Dec; 54(6):1937-1949. PubMed ID: 33991378
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease.
Lee SJ; Kim SU
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):523-530. PubMed ID: 31018719
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
17. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
Ajmera VH; Liu A; Singh S; Yachoa G; Ramey M; Bhargava M; Zamani A; Lopez S; Mangla N; Bettencourt R; Rizo E; Valasek M; Behling C; Richards L; Sirlin C; Loomba R
Hepatology; 2020 Mar; 71(3):849-860. PubMed ID: 31556124
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease.
Choi SJ; Kim SM; Kim YS; Kwon OS; Shin SK; Kim KK; Lee K; Park IB; Choi CS; Chung DH; Jung J; Paek M; Lee DH
Diabetes Metab J; 2021 Sep; 45(5):739-752. PubMed ID: 33108854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
